Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gilead Sciences is conducting a clinical study titled A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The study aims to assess the effectiveness, safety, and tolerability of Tenofovir Alafenamide (TAF) compared to a placebo in children and teens with chronic hepatitis B, as well as to determine appropriate dosing levels for children.
The intervention being tested is Tenofovir Alafenamide (TAF), an antiviral drug administered orally once daily. The study includes experimental groups receiving TAF and placebo groups for comparison, with an open-label extension phase for further evaluation.
This interventional study follows a randomized, parallel assignment model with double masking, meaning both participants and investigators are unaware of group assignments. The primary purpose of the study is treatment-focused.
The study began in November 2016, with primary completion expected in the future. The latest update was submitted in July 2025, indicating ongoing recruitment and data collection.
The outcome of this study could significantly impact Gilead Sciences’ stock performance by potentially expanding their market share in pediatric antiviral treatments. Competitors in the antiviral space may also be affected, depending on the study’s results and subsequent regulatory approvals.
The study is currently ongoing, with further details available on the ClinicalTrials portal.